Open Access

Gene therapy for haemophilia: an update on progress in clinical trials

   | Apr 21, 2018


1. Cancio MI, Reiss UM, Nathwani AC, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet 2013; 6: 91-101. doi: 10.2147/TACG.S31928.Search in Google Scholar

2. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia 2014; 20(4): 459-63. doi: 10.1111/hae.12375.Search in Google Scholar

3. Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K.Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia 2013 5; 19(3): 355-6. doi: 10.1111/hae.12079.Search in Google Scholar

4. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for haemophilia. Hematology Am Soc Hematol Educ Program 2013; 2013: 30-6. doi: 10.1182/asheducation-2013.1.30.Search in Google Scholar

5. Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost 2013; 11 Suppl 1: 99-110. doi: 10.1111/jth.12215.Search in Google Scholar

6. Porada CD, Stem C, Almeida-Porada G. Gene Therapy; The promise of a permanent cure. N C Med J 2013; 74(6): 526-9.10.18043/ncm.74.6.526Search in Google Scholar

7. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5(1): 64-70.10.1038/47519883841Open DOISearch in Google Scholar

8. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99(8): 2670-6.10.1182/blood.V99.8.267011929752Search in Google Scholar

9. High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012; 120(23): 4482-7. doi: 10.1182/blood-2012-05-423210.Search in Google Scholar

10. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy Blood 2013; 122(1): 23-36. doi: 10.1182/blood-2013-01-306647.Search in Google Scholar

11. Roth DA, Tawa NE, O’Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe haemophilia A. N Engl J Med 2001; 344(23): 1735-1742.10.1056/NEJM20010607344230111396439Search in Google Scholar

12. Powell JS, Ragni MV, White GC, et al. Phase 1 trial of FVIII gene transfer for severe haemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102(6): 2038-2045.10.1182/blood-2003-01-016712763932Search in Google Scholar

13. White GC, Monahan PE. Gene therapy for haemophilia A. In: Lee CA, Berntorp EE, Hoots K, editors. Textbook of Haemophilia. 2nd ed. Hoboken, NJ: Wiley- Blackwell; 2005.Search in Google Scholar

14. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe haemophilia B. Blood 2003; 101(8): 2963- 297210.1182/blood-2002-10-329612515715Search in Google Scholar

15. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3): 342-347.10.1038/nm135816474400Open DOISearch in Google Scholar

16. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65. doi: 10.1056/NEJMoa1108046.Search in Google Scholar

17. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004. doi: 10.1056/NEJMoa1407309.Search in Google Scholar

18. in Google Scholar

19. Pick A, Gilbert K, McCaul J. The role of effective communication in achieving informed consent for clinical trials. Nurs Stand 2014 Nov 5;29(10):45-8. doi: 10.7748/ns.29.10.45.e9443.Search in Google Scholar

Publication timeframe:
Volume Open
Journal Subjects:
Medicine, Basic Medical Science, other, Clinical Medicine, Pharmacy, Pharmacology